Neurogenic inflammation. I. Basic mechanisms, physiology and pharmacology;Die neurogene entzündung. I. Grundlegende mechanismen, physiologie und pharmakologie

Anasthesiologie Intensivmedizin Notfallmedizin Schmerztherapie

Volumn 37, Issue 6, 2002, Pages 314-325

  Herbert, Michael K ^a   Holzer, P ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF GRAZ   (Austria)

Author keywords

Axon reflex; CGRP; Neurogenic inflammation; Sensory nerve fibres; Substance P

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; CAPSAICIN; NEUROPEPTIDE; SUBSTANCE P; VANILLOID RECEPTOR;

ANTIDROMIC STIMULATION; CLINICAL PHARMACOLOGY; EDEMA; ERYTHEMA; HUMAN; HYPEREMIA; INFLAMMATION; MYELINATION; NERVE ENDING; NERVE FIBER; NEUROLOGIC DISEASE; NOCICEPTIVE STIMULATION; NONHUMAN; PATHOPHYSIOLOGY; PEPTIDE ANALYSIS; PERIPHERAL NERVE; PERIPHERAL NERVOUS SYSTEM; PROTEIN SECRETION; REVIEW; SENSORY NERVE; SENSORY STIMULATION;

ANIMALS; CALCITONIN GENE-RELATED PEPTIDE; CAPSAICIN; HUMANS; INFLAMMATION; NERVE FIBERS; NEURITIS; NEURONS, AFFERENT; SUBSTANCE P;

EID: 0036083303     PISSN: 09392661     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-32233     Document Type: Review

References (185)

1. Mode of action of nociceptors
2. Cutaneous mechanoreceptors and nociceptors
3. Experiments relating to cutaneous hyperalgesia and its spread through somatic nerves
4. Über die beziehung der sensiblen nervenendigungen zum entziindungsvorgang
5. Direct evidence for neurogenic inflammation and its prevention by denervation and pretreatment with capsaicin
6. Untersuchungen über die gefässwurzel des ischiadicus
7. On the origin from the spinal cord of vasodilator fibers of the hind limb, and on the nature of these fibers
8. Vasodilator axon-reflexes
9. Die pathogenese der trophischen gewebeschadens nach der nervenverletzung
10. The role of sensory nerve endings in neurogenic inflammation induced in human skin and in the eye and paw of the rat
11. Dorsal root reflexes and cutaneous neurogenic inflammation after intradermal injection of capsaicin in rats
12. Axonal transport of substance P in the vagus and sciatic nerves of the guinea pig
13. Calcitonin gene-related peptide immunoreactivity in the spinal cord of man and of eight other species
14. Pituitary adenylate cyclase activating peptide is a sensory neuropeptide: Umminocytochemical and immunochemical evidence
15. Peptidergic sensory neurons in the control of vascular functions: Mechanisms and significance in the cutaneous and splanchnic vascular beds
16. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing
17. Tachykinin receptors and tachykinin receptor antagonists
18. Neurotransmitter functions of mammalian tachykinins
19. Regional distribution of substance P, neurokinin alpha and neurokinin beta in rat spinal cord, nerve roots and dorsal root ganglia, and the effects of dorsal root section or spinal transection
20. Peptide- and non- peptide-containing unmyelinated primary afferents: The parallel processing of nociceptive information
21. Immunoelectron microscopic study of substance P-containing fibers in feline cerebral arteries
22. Presence of calcitonin gene-related peptide (CGRP) and substance P (SP) immunoreactivity in intraepidermal free nerve endings of cat skin
23. A light and electron microscopic study of calcitonin gene-related peptide in the spinal cord of the rat
24. Immunoreactive calcitonin gene-related peptide and substance P coexist in sensory neurons to the spinal cord and interact in spinal behavioral responses of the rat
25. Coexistence of calcitonin gene-related peptide and substance P-like peptide in single cells of the trigeminal ganglion of the rat: Immunohistochemical analysis
26. Colocalization of calcitonin gene-related peptide-like immunoreactivity with substance P in cutaneous, vascular and visceral sensory neurons of guinea pigs
27. Two immunohistochemically identified populations of calcitonin gene-related peptide (CGRP)-immunoreactive axons in human skin
28. The coexistence of neuropeptides in feline sensory neurons
29. Calcitonin gene-related peptide, substance P and nitric oxide are involved in cutaneous inflammation following ultraviolet irradiation
30. The contribution of sensory nerves to xylene-induced cystitis in rats
31. Neurogenic vasodilation in the rat hairy skin measured using a laser Doppler flowmeter
32. Increase of blood flow in skin and spinal cord following activation of small diameter primary afferents
33. Neurogenic hyperalgesia: The search for the primary cutaneous afferent fibers that contribute to capsaicin-induced pain and hyperalgesia
34. Neurogenic hyperalgesia: Psychophysical studies of underlying mechanisms
35. Pain, hyperalgesia and activity in nociceptive C units in humans after intradermal injection of capsaicin
36. Development of secondary hyperalgesia following non-painful thermal stimulation of the skin: A psychophysical study in man
37. Sensory neuropeptides in the skin
38. Neurogenic oedema and vasodilatation: Effect of a selective neuronal NO inhibitor
39. Electrically evoked neuropeptide release and neurogenic inflammation differ between rat and human skin
40. Neurogenic inflammation in human and rodent skin
41. Zur frage der zentralen übertragung afferenter impulse-III. Mitteilung. das vorkommen und die bedeutung der substanz P in den dorsalen wurzeln des rückenmarks
42. Antidromic vasodilatation and neurogenic inflammation
43. Local effector functions of capsaicin-sensitive sensory nerve endings: Involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides
44. Endothelial-dependent relaxant actions of carbachol and substance P in arterial smooth muscle
45. Local mechanisms of blood flow control by perivascular nerves and endothelium
46. Substance P as neurogenic mediator of antidromic vasodilation and neurogenic plasma extravasation
47. Substance P - A putative mediator of antidromic vasodilation
48. Electron microscopical evidence for a direct contact between nerve fibres and mast cells
49. Suggestive evidence for a direct innervation of mucosal mast cells
50. Exogenous but not endogenous substance P releases histamine from isolated human skin fragments
51. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing
52. Sensory and autonomic innervation of non-hairy and hairy human skin. An immunohistochemical study
53. Distribution and fine structure of calcitonin gene-related peptide-like immunoreactive nerve fibers in the rat skin
54. Localization and effects of neuropeptide Y, vasoactive intestinal polypeptide, substance P, and calcitonin gene-related peptide in human temporal arteries
55. Calcitonin gene-related peptide (CGRP): Perivascular distribution and vasodilatory effects
56. Substance P- and CGRP-immunoreactive nerves in bone
57. Calcitonin gene related peptide released from dural nerve fibers mediates increase of meningeal blood flow in the rat
58. Peptide-containing nerve fibres in human extracranial tissue: A morphological basis for neuropeptide involvement in extracranial pain?
59. Calcitonin gene-related peptide: Multiple actions, multiple receptors
60. Calcitonin gene-related peptide is a potent vasodilator
61. Potent vasodilator activity of calcitonin gene-related peptide in human skin
62. Substance P. calcitonin gene-related peptide: Immunohistochemical localisation and microvascular effects in rabbit skeletal muscle
63. Calcitonin gene-related peptide, neurokinin A and substance P: Effects on nociception and neurogenic inflammation in human skin and temporal muscle
64. Sensory neuropeptide effects in human skin
65. Some effects of calcitonin gene-related peptide in human skin and on histamine release
66. Effects of substance P, neurokinin A and calcitonin gene-related peptide in human skin and their involvement in sensory nerve-mediated responses
67. Nitric oxide and sensory nerves are involved in the vasodilator response to acetylcholine but not calcitonin gene-related peptide in rat skin microvasculature
68. Trigeminal ganglion stimulation increases facial skin blood flow in the rat: A major role for the calcitonin gene-related peptide
69. Relative involvement of substance P and CGRP mechanisms in antidromic vasodilation in the rat skin
70. Neurogenic vasodilatation and plasma leakage in the skin
71. Substance P regulates the vasodilator activity of calcitonin gene-related peptide
72. No release of histamine and substance P in capsaicin-induced neurogenic inflammation in intact human skin in vivo: A microdialysis study
73. Plasma extravasation and neuropeptide release in human skin as measured by intradermal microdialysis
74. Temporal characteristics of capsaicin sensitization and desensitization on the tongue
75. Capsaicin-sensitive non-cholinergic excitatory innervation of the guinea-pig tracheobronchial smooth muscle
76. Capsaicin challenge, reflex bronchoconstriction, and local action of substance P
77. Reflex responses to capsaicin: Intravenous, aerosol, and intratracheal administration
78. Excitation by irritant chemical substances of sensory afferent units in the cat's cornea
79. Capsaicin: Cellular targets, mechanisms of action, and selectivity for thin sensory neurons
80. New type of nerve-mediated cholinergic contractions of the guinea-pig small intestine and its selective blockade by capsaicin
81. Dose-dependent effects of capsaicin on primary sensory neurons in the neonatal rat
82. The neuropharmacology of capsaicin: Review of some recent observations
83. Neonatal capsaicin is not a specific neurotoxin for sensory C-fibres or small dark cells of rat dorsal root ganglia
84. Selective degeneration by capsaicin of a subpopulation of primary sensory neurons in the adult rat
85. The time course and specificity of the changes in the behavioural and dorsal horn cell responses to noxious stimuli following peripheral nerve capsaicin treatment in the rat
86. The sensory response to capsaicin during repeated topical exposures: Differential effects on sensations of itching and pungency
87. The sensory-efferent function of capsaicin-sensitive sensory neurons
88. Effect of topical application with capsaicin on skin responses to bradykinin and histamine in man
89. Thermoregulatory effects of resiniferatoxin in the mouse: Comparison with capsaicin
90. Vanilloid receptors: New insights enhance potential as a therapeutic target
91. Resiniferatoxin and analogs provide novel insights into the pharmacology of the vanilloid (capsaicin) receptor
92. The vanilloid receptor
93. Resiniferatoxin, an ultrapotent selective modulator of capsaicin-sensitive primary afferent neurons
94. Capsazepine: A competitive antagonist of the sensory neurone excitant capsaicin
95. The vanilloid (capsaicin) receptor: Receptor types and species differences
96. Capsazepine reversal of the antinociceptive action of capsaicin in vivo
97. Capsazepine, a novel capsaicin antagonist, selectively antagonises the effects of capsaicin in the mouse spinal cord in vitro
98. Capsazepine inhibits cough induced by capsaicin and citric acid but not by hypertonic saline in guinea pigs
99. Ruthenium red and capsazepine aninociceptive effect in formalin and capsaicin midels of pain in mice
100. A spinal mechanism of action is involved in the antinociception produced by the capsaicin analogue NE 19550 (olvanil)
101. Cutaneous pretreatment with the capsaicin analog NE-21610 prevents the pain to a burn and subsequent hyperalgesia
102. Antinociception induced by civamide, an orally active capsaicin analogue
103. 3H]resiniferatoxin autoradiography of capsaicin-sensitive neurons in the rat, pig, and man
104. 3H] resiniferatoxin binding of a human vanilloid (capsaicin) receptor in post-mortem spinal cord
105. The capsaicin receptor: A heat activated ion channel in the pain pathway
106. Capsaicin-induced ion fluxes in dorsal root ganglion cells in culture
107. Protons: Small stimulants of capsaicin sensitive sensory nerves
108. Effect of protons on the inward current evoked by capsaicin in isolated dorsal root ganglion cells
109. Low pH facilitates capsaicin responses in isolated sensory neurones of the rat
110. Capsaicin binds to the intracellular domain of the capsaicin-activated ion channel
111. Anandamide activates vanilloid receptor 1 (VR1) at acidic ph in dorsal root ganglia neurons and cells ectopically expressing VR1
112. Temperature-dependent activation of recombinant rat vanilloid VR1 receptors expressed in HEK293 cells by capsaicin and anandamide
113. New perspectives on enigmatic vanilloid receptors
114. The endogenous lipid anandamide is a full agonist at the human vailloid receptor (hVR1)
115. Protein kinase C activation potentiates gating of the vanilloid receptor VR1 by capsaicin, protons, heat and anandamide
116. The postmastectomy pain syndrome and topical capsaicin: A randomized trial
117. The post-mastectomy pain syndrome and the effect of topical capsaicin
118. Topical capsaicin. A review of its pharmacological properties and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy and osteoarthritis
119. Treatment of meralgia paraesthetica with topical capsaicin
120. Double-blind, placebo-controlled study of the application of capsaicin cream in chronic distal painful neuropathy
121. The tachykinin NK1 receptor Part 1: Ligands and mechanisms of cellular activation
122. The effect of a specific tachykinin receptor antagonist FK-224 on ozone-induced airway hyperresponsiveness and inflammation
123. 1 antagonists: From discovery to the clinic
124. The pharmacology of the efferent function of sensory nerves
125. Tachykinins as peripheral modulators of primary afferent nerves and visceral sensitivity
126. The tachykinin NK1 receptor. Part II: Distribution and pathophysiological roles
127. Warum versagen Substanz P (NK(1)-Rezeptor-antagonisten in der Schmerztherapie?
128. Tachykinin antagonists and the airways
129. Modulation of neurogenic inflammation: Novel approaches to inflammatory disease
130. The inhibition of neurogenic inflammation
131. Polypeptide-containing neurons in airway smooth muscle
132. The 1988 Ulf Euler Lecture. Substance P: From extract to excitement
133. Inhibition of neurogenic plasma exudation in guinea-pig airways by CP-96,345, a new non-peptide NK1 receptor antagonist
134. The non-peptide tachykinin antagonist, CP-96,345, is a potent inhibitor of neurogenic inflammation
135. Release of somatostatin and ist role in the mediation of the anti-inflammatory effect induced by antidromic stimulation of sensory fibres of rat sciatic nerve
136. Systemic anti-inflammatory effect induced by antidromic stimulation of the dorsal roots in the rat
137. Regulation of substance P release mediated by prejunctional histamine H3 receptors
138. Inhibition of the neurogenic inflammatory response by lidocaine in rat skin
139. Capsaicin-induced desensitization of airway mucosa to cigarette smoke, mechanical and chemical irritants
140. Experimental treatments for asthma
141. Effects of the bradykinin B2 receptor antagonist S16118 (p-guanidobenzoyl-[Hyp3,Thi5,D-Ti-c7, Oic8]bradykinin) in different in vivo animal models of inflammation
142. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater
143. Further characterization of the putative 5-HT receptor which mediates blockade of neurogenic plasma extravasation in rat dura mater
144. CP-93,129, a potent and selective 5-HT1 B receptor agonist blocks neurogenic plasma extravasation within rat but not guinea-pig dura mater
145. Effect of a 5-HT1 receptor agonist, CP-122,288, on oedema formation induced by stimulation of the rat saphenous nerve
146. Dual effects of the serotonin agonist, sumatriptan, on peripheral neurogenic inflammation
147. Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura mater
148. Cyclooxygenase inhibitors acetylsalicylic acid and indomethacin do not affect capsaicin-induced neurogenic inflammation in human skin
149. Peripheral mechanisms of opioid analgesia
150. Sensory pharmacology
151. Involvement of capsaicin-sensitive neurones in hyperalgesia and enhanced opioid antinociception in inflammation
152. Inhibition by nociceptin of neurogenic inflammation and the release of SP and CGRP from sensory nerve terminals
153. Characterization of ruthenium red as an inhibitor of neurogenic inflammation in the rat trachea
154. Capsaicin-induced stimulation of polymodal nociceptors is antagonized by ruthenium red independently of extracellular calcium
155. Activation of primary afferent neurons by thermal stimulation. Influence of ruthenium red
156. Inhaled cromoglycate reduces airway neurogenic inflammation via tachykinin antagonism
157. Enhancement of phagocytosis - A newly found activity of substance P residing in its N-terminal tetrapeptide sequence
158. Activation of macrophages by substance P: Induction of oxidative burst and thromboxane release
159. Modulation of lymphocyte function by sensory neuropeptides
160. Substance P: Binding properties and studies on cellular responses in guinea pig macrophages
161. Differential effects of vasoactive intestinal peptide, substance P, and somatostatin on immunoglobulin synthesis and proliferations by lymphocytes from Peyer's patches, mesenteric lymph nodes, and spleen
162. Interleukin Interleukin-1 beta as a potent hyperalgesic agent antagonized by a tripeptide analogue
163. The pivotal role of tumour necrosis factor alpha in the development of inflammatory hyperalgesia
164. Isolation of an interleukin-1-like factor from human joint effusions
165. Cytokines and the chronic inflammation of rheumatic disease. I. The presence of interleukin-1 in synovial fluids
166. Interleukin 1 activity produced by human rheumatoid and normal dendritic cells
167. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis
168. Cytokines in synovial fluid. 1. The presence of biologically active and immunoreactive IL-1
169. Cytokine production in the rheumatoid joint: Implications for treatment
170. Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon
171. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum
172. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis
173. Identification of the major fibroblast growth factors released spontaneously in inflammatory arthritis as platelet derived growth factor and tumour necrosis factor-alpha
174. Circulating tumor necrosis factor alpha in rheumatoid arthritis
175. Interleukin-1 β enhances capsaicin-induced neurogenic vasodilatation in the rat skin
176. Nitric oxide mediates the amplification by interleukin-1 β of neurogenic vasodilatation in the rat skin
177. Tumor necrosis factor a prevents interleukin-1 β from augmenting capsaicin-induced vasodilatation in the rat skin
178. Inhibition by neuropeptides of interleukin-1 beta-induced, prostaglandin-independent hyperalgesia
179. Interleukin-1 enhances pain reflexes. Mediation through increased prostaglandin E2 levels
180. Clinical pharmacology of recombinant tumor necrosis factor in patients with advanced cancer
181. Preliminary report: Effects of interleukin-1 on platelet counts
182. The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies